Selection of heterocycles for drug design

被引:97
作者
Broughton, HB
Watson, IA
机构
[1] Lilly SA, Madrid 28108, Spain
[2] Eli Lilly Corp Ctr, Indianapolis, IN 46225 USA
关键词
heterocycle; diversity; similarity; library design; descriptors; properties; known drugs; ring systems; ADME; ADMET; absorption; distribution; metabolism; excretion; toxicity;
D O I
10.1016/j.jmgm.2004.03.016
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A method has been devised to obtain heterocyclic ring systems suitable for use in drug design and library design, with an emphasis on the selection of systems with good absorption, distribution, metabolism, excretion and toxicity (ADMET) properties in man. This has been achieved by extraction of the ring systems found in drugs that have reached Phase II or later stages of drug development and launch. Properties have been calculated for these ring systems to enable them to be rationally selected from the database, including descriptors based on molecular size, shape, hydrogen bonding and orbital properties. In many cases, the properties have been calculated for different attachment points of the same heterocycle. Principal components analysis has been used to enable visualization of the set of heterocycles in a useful "chemical space". Using this space, it is possible to select heterocycles for drug design to explore specific aspects of the properties of the heterocycle, such as size or hydrogen bonding, while maintaining other parameters near constant, or to select heterocycles with extreme values of these properties but which are nonetheless likely to be acceptable in a drug. The differences between the properties calculated for the most- and least-frequently used heterocycles from the late-phase drug set have been analyzed, and may suggest that heterocycles in successful drugs are more likely to have calculated quantities associated with lower chemical reactivity. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:51 / 58
页数:8
相关论文
共 15 条
  • [1] The properties of known drugs .1. Molecular frameworks
    Bemis, GW
    Murcko, MA
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (15) : 2887 - 2893
  • [2] Scaffold searching: Automated identification of similar ring systems for the design of combinatorial libraries
    Bohl, M
    Dunbar, J
    Gifford, EM
    Heritage, T
    Wild, DJ
    Willett, P
    Wilton, DJ
    [J]. QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS, 2002, 21 (06): : 590 - 597
  • [3] *DAYL CHEM INF SYS, MISS VIEJ
  • [4] Towards a new age of virtual ADME/TOX and multidimensional drug discovery
    Ekins, S
    Boulanger, B
    Swaan, PW
    Hupcey, MAZ
    [J]. MOLECULAR DIVERSITY, 2000, 5 (04) : 255 - 275
  • [5] FRISCH MJ, GAUSSIAN 98 REVISION
  • [6] Principal components describing biological activities and molecular diversity of heterocyclic aromatic ring fragments
    Gibson, S
    McGuire, R
    Rees, DC
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (20) : 4065 - 4072
  • [7] Experimental designs for selecting molecules from large chemical databases
    Higgs, RE
    Bemis, KG
    Watson, IA
    Wikel, JH
    [J]. JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES, 1997, 37 (05): : 861 - 870
  • [8] The combinatorial synthesis of bicyclic privileged structures or privileged substructures
    Horton, DA
    Bourne, GT
    Smythe, ML
    [J]. CHEMICAL REVIEWS, 2003, 103 (03) : 893 - 930
  • [9] Drug rings database with web interface. A tool for identifying alternative chemical rings in lead discovery programs
    Lewell, XQ
    Jones, AC
    Bruce, CL
    Harper, G
    Jones, MM
    Mclay, LM
    Bradshaw, J
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (15) : 3257 - 3274
  • [10] Exploring chemical rings in a simple topological-descriptor space
    Lipkus, AH
    [J]. JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES, 2001, 41 (02): : 430 - 438